Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iDAP Injection for Parkinson's Disease
NCT06583291Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label trial of iDAP in Parkinson's disease (PD) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Incidence and severity of adverse events at 24 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
iDAP
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06583291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583291.